- Trials with a EudraCT protocol (49)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
49 result(s) found for: Window of opportunity.
Displaying page 1 of 3.
EudraCT Number: 2013-000674-30 | Sponsor Protocol Number: 2013-000674-30 | Start Date*: 2013-07-24 |
Sponsor Name:AOU SAN LUIGI GONZAGA - SCDU ONCOLOGIA MEDICA | ||
Full Title: Multicenter clinical trial, randomized phase II "window of opportunity" which aims to test the biological activity of abiraterone acetate administered as neoadjuvant therapy in patients with prosta... | ||
Medical condition: PROSTATE CANCER PATIENTS WITH HIGH RISK | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: IT (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-004121-80 | Sponsor Protocol Number: | Start Date*: 2019-02-05 | |||||||||||
Sponsor Name:The Christie Hospital NHS Foundation Trust | |||||||||||||
Full Title: A proof of concept, window trial of the IMmunological effects of AveLumab and Aspirin in Triple-Negative Breast Cancer. | |||||||||||||
Medical condition: Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-000543-13 | Sponsor Protocol Number: UoL001204 | Start Date*: 2016-12-28 | ||||||||||||||||
Sponsor Name:University of Liverpool | ||||||||||||||||||
Full Title: A window of opportunity study to assess the biological effects of enobosarm in oestrogen receptor positive, androgen receptor positive early breast cancer | ||||||||||||||||||
Medical condition: oestrogen receptor, androgen receptor positive early breast cancer | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Under 18, Adults | Gender: Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001521-41 | Sponsor Protocol Number: UoL001304 | Start Date*: 2017-09-18 | |||||||||||
Sponsor Name:University of Liverpool | |||||||||||||
Full Title: A window of opportunity study to assess the biological effects of progesterone in premenopausal ER-positive, PgR-positive early breast cancer | |||||||||||||
Medical condition: Premenopausal ER-positive, PgR-positive early breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002077-21 | Sponsor Protocol Number: ICR-CTSU/2017/10065 | Start Date*: 2019-04-18 | |||||||||||
Sponsor Name:The Institute of Cancer Research | |||||||||||||
Full Title: PHOENIX Trial: A pre-surgical window of opportunity and post-surgical adjuvant biomarker study of DNA damage response inhibition and/or anti-PD-L1 immunotherapy in patients with neoadjuvant chemoth... | |||||||||||||
Medical condition: Triple Negative Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-003628-20 | Sponsor Protocol Number: 0705/789 | Start Date*: 2005-11-10 |
Sponsor Name:West Yorkshire Primary Care R&D Unit | ||
Full Title: The Shoulder Window of Opportunity Study (SWOP) - A pragmatic randomised trial comparing corticosteroid injection with timely physiotherapy with physiotherapy alone for older subjects with subacrom... | ||
Medical condition: Subacromial impingement syndrome | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000112-21 | Sponsor Protocol Number: MESI-STRAT-WOO | Start Date*: 2018-09-03 | |||||||||||
Sponsor Name:Ruprecht-Karls-Universität Heidelberg, Medizinische Fakultät, vertreten durch das Universitätsklinikum Heidelberg | |||||||||||||
Full Title: Prospective Window of opportunity trial 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer | |||||||||||||
Medical condition: (ER+) Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005101-12 | Sponsor Protocol Number: AGO-OVAR27 | Start Date*: 2021-11-09 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:AGO Research GmbH | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: Window-of-opportunity proof-of-concept, non-randomized, open-label phase II trial of Olaparib given alone (cohort A) or in combination with Durvalumab (cohort B) prior to primary debulking surgery ... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Patients with presumed and previously untreated advanced stage ovarian cancer planned to undergo laparoscopy for histologic diagnosis and treatment planning. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: DE (Trial now transitioned) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003960-22 | Sponsor Protocol Number: WOO2 | Start Date*: 2021-03-15 | |||||||||||
Sponsor Name:Medical University of Innsbruck | |||||||||||||
Full Title: Prospective Window of opportunity trial of 3 weeks neoadjuvant Anastrozole in Postmenopausal Women with Estrogen receptor positive (ER+) Breast Cancer | |||||||||||||
Medical condition: (ER+) Breast Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-000120-19 | Sponsor Protocol Number: HN1901 | Start Date*: 2020-05-05 |
Sponsor Name:Cliniques universitaires Saint-Luc | ||
Full Title: Activity and safety of peptide-based immunotherapy in an umbrella window pre-operative opportunity phase II study in patients with squamous cell carcinoma of the head and neck. | ||
Medical condition: Head and neck cancer elective for surgery | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2018-003056-21 | Sponsor Protocol Number: WIRE | Start Date*: 2020-02-07 | ||||||||||||||||
Sponsor Name:Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge | ||||||||||||||||||
Full Title: Window-of-opportunity clinical trials platform for evaluation of novel treatment strategies in renal cell cancer. | ||||||||||||||||||
Medical condition: Surgically resectable renal cell cancer (Stage M0/M1) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002001-37 | Sponsor Protocol Number: 009684QM | Start Date*: 2015-03-03 | |||||||||||
Sponsor Name:Queen Mary University London | |||||||||||||
Full Title: Phase II window of opportunity study of short term preoperative treatment with enzalutamide (alone or in combination with exemestane) in patients with primary breast cancer. | |||||||||||||
Medical condition: Primary breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001634-36 | Sponsor Protocol Number: SARCOVID | Start Date*: 2020-04-09 |
Sponsor Name:Rosario García de Vicuña | ||
Full Title: Randomized open pilot study to evaluate the efficacy of subcutaneous sarilumab in patients with moderate-severe COVID-19 infection. | ||
Medical condition: COVID-19 infection requiring hospitalization | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-003739-12 | Sponsor Protocol Number: NICOLE | Start Date*: 2018-01-29 | |||||||||||||||||||||
Sponsor Name:SOCIETà CAMPANA DI IMMUNOTERAPIA ONCOLOGICA | |||||||||||||||||||||||
Full Title: Preoperative Nivolumab in patients with locally advanced colon cancer (T3 or T4): a window-of-opportunity study | |||||||||||||||||||||||
Medical condition: colon cancer: a window-of-opportunity study | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000298-11 | Sponsor Protocol Number: ISS22810078 | Start Date*: 2015-09-02 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA "ISTITUTI OSPITALIERI" DI CREMONA | |||||||||||||
Full Title: A phase II, open label, controlled study of olaparib in locally advanced ER, PgR and HER2 negative (Triple Negative) and in locally advanced germline BRCA mutation-positive breast cancer patients: ... | |||||||||||||
Medical condition: Locally advanced breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-005193-11 | Sponsor Protocol Number: METAL | Start Date*: 2015-03-31 | |||||||||||
Sponsor Name:King's College London [...] | |||||||||||||
Full Title: METformin And Longevity (METAL): A window of opportunity study investigating biological effects of metformin in localised prostate cancer | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-005487-26 | Sponsor Protocol Number: AI468-038 | Start Date*: 2015-07-03 | |||||||||||
Sponsor Name:ViiV Healthcare UK Limited | |||||||||||||
Full Title: A Phase 2b Randomized, Active-Controlled, Double-Blind Trial to Investigate Safety, Efficacy and Dose-response of BMS-955176, Given on a Backbone of Tenofovir/Emtricitabine, in Treatment-Naive HIV-... | |||||||||||||
Medical condition: HIV | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) ES (Completed) GB (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004961-42 | Sponsor Protocol Number: BC-6226 | Start Date*: 2020-08-06 | |||||||||||
Sponsor Name:Ghent University Hospital | |||||||||||||
Full Title: SPondyloArthritis: inducing drug-free Remission by early TNF-Alpha bloCkade Under guidance of Single cell RNA sequencing and epigenetic profiling | |||||||||||||
Medical condition: peripheral spondyloarthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003319-12 | Sponsor Protocol Number: ICR-CTSU-2014-10046 | Start Date*: 2015-03-27 | |||||||||||
Sponsor Name:The Royal Marsden NHS Foundation Trust [...] | |||||||||||||
Full Title: Window study of the PARP inhibitor rucaparib in patients with primary triple negative or BRCA1/2 related breast cancer (RIO) | |||||||||||||
Medical condition: Primary breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-000569-21 | Sponsor Protocol Number: GS-US-417-0302 | Start Date*: 2017-01-30 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 weeks in Combination with Conventional Synthetic Disea... | |||||||||||||
Medical condition: Moderately to severely active rheumatoid arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) GB (Completed) DE (Completed) FR (Completed) HU (Completed) ES (Completed) PL (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
